Details

Autor(en) / Beteiligte

• Collier, Dami A
• De Marco, Anna
• Ferreira, Isabella A T M
• Meng, Bo
• Datir, Rawlings P
• Walls, Alexandra C
• Kemp, Steven A
• Bassi, Jessica
• Pinto, Dora
• Silacci-Fregni, Chiara
• Bianchi, Siro
• Tortorici, M Alejandra
• Bowen, John
• Culap, Katja
• Jaconi, Stefano
• Cameroni, Elisabetta
• Snell, Gyorgy
• Pizzuto, Matteo S
• Pellanda, Alessandra Franzetti
• Garzoni, Christian
• Riva, Agostino
• Elmer, Anne
• Kingston, Nathalie
• Graves, Barbara
• McCoy, Laura E
• Smith, Kenneth G C
• Bradley, John R
• Temperton, Nigel
• Ceron-Gutierrez, Lourdes
• Barcenas-Morales, Gabriela
• Harvey, William
• Virgin, Herbert W
• Lanzavecchia, Antonio
• Piccoli, Luca
• Doffinger, Rainer
• Wills, Mark
• Veesler, David
• Corti, Davide
• Gupta, Ravindra K

Titel

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Ist Teil von

• Nature (London), 2021-05, Vol.593 (7857), p.136-141

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded in some areas by the higher transmission potential of the B.1.1.7 variant , which has now been reported in 94 countries. It is unclear whether the response of the virus to vaccines against SARS-CoV-2 on the basis of the prototypic strain will be affected by the mutations found in B.1.1.7. Here we assess the immune responses of individuals after vaccination with the mRNA-based vaccine BNT162b2 . We measured neutralizing antibody responses after the first and second immunizations using pseudoviruses that expressed the wild-type spike protein or a mutated spike protein that contained the eight amino acid changes found in the B.1.1.7 variant. The sera from individuals who received the vaccine exhibited a broad range of neutralizing titres against the wild-type pseudoviruses that were modestly reduced against the B.1.1.7 variant. This reduction was also evident in sera from some patients who had recovered from COVID-19. Decreased neutralization of the B.1.1.7 variant was also observed for monoclonal antibodies that target the N-terminal domain (9 out of 10) and the receptor-binding motif (5 out of 31), but not for monoclonal antibodies that recognize the receptor-binding domain that bind outside the receptor-binding motif. Introduction of the mutation that encodes the E484K substitution in the B.1.1.7 background to reflect a newly emerged variant of concern (VOC 202102/02) led to a more-substantial loss of neutralizing activity by vaccine-elicited antibodies and monoclonal antibodies (19 out of 31) compared with the loss of neutralizing activity conferred by the mutations in B.1.1.7 alone. The emergence of the E484K substitution in a B.1.1.7 background represents a threat to the efficacy of the BNT162b2 vaccine.